Consistent with previous reports, vemurafenib treatment enhanced ERBB3 expression and improved the sensitivity of melanoma cells to ERBB3 ligand, NRG1, as assessed by the phosphorylation of AKT (Fig. 7a). This evidence concerns the gene AKT1 and melanoma.